VRNA — Verona Pharma Income Statement
0.000.00%
Last trade - 00:00- $5.54bn
- $5.26bn
- $42.28m
Annual income statement for Verona Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 40 | 0.458 | 0 | 42.3 |
| Cost of Revenue | |||||
| Gross Profit | — | — | 0.112 | 0 | 39.7 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 74.3 | 113 | 77 | 67.6 | 201 |
| Operating Profit | -74.3 | -73.3 | -76.6 | -67.6 | -158 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -65 | -55.6 | -68.4 | -53.9 | -163 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -65.1 | -55.6 | -68.7 | -54.4 | -173 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -65.1 | -55.6 | -68.7 | -54.4 | -173 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -65.1 | -55.6 | -68.7 | -54.4 | -173 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.25 | -0.117 | -0.129 | -0.086 | -0.262 |